III | Jotup

Ault Alliance’s Subsidiary, Sentinum, Completes Unit Testing for High-Performance Computing and Artificial Intelligence Infrastructure

Retrieved on:

Thursday, October 26, 2023

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance,” or the “Company”), is pleased to announce that its wholly owned subsidiary, Sentinum, Inc. (“Sentinum”) has successfully completed unit testing on critical infrastructure components necessary to meet the power demands of high-performance computing (“HPC”) and artificial intelligence (“AI”) applications.

Key Points:

Ault Alliance, Inc. (NYSE American: AULT), a diversified holding company (“Ault Alliance,” or the “Company”), is pleased to announce that its wholly owned subsidiary, Sentinum, Inc. (“Sentinum”) has successfully completed unit testing on critical infrastructure components necessary to meet the power demands of high-performance computing (“HPC”) and artificial intelligence (“AI”) applications.
Sentinum is now fully prepared to deploy and provide support for enterprise-class servers and storage devices through its subsidiary, Alliance Cloud Services, LLC.
These services will be delivered from Sentinum’s state-of-the-art data center, located within a 617,000 square foot facility on a 34.5 acre site in southern Michigan.
William B. Horne, Chief Executive Officer of Ault Alliance, expressed, “This marks another crucial step in our strategy to diversify the offerings available through our Michigan data center.

Galderma Phase III Data Published in the New England Journal of Medicine: Full OLYMPIA 2 Trial Results Demonstrate Nemolizumab’s Rapid Onset of Action in Prurigo Nodularis Patients

Retrieved on:

Thursday, October 26, 2023

Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Prurigo, Nemolizumab, Safety, Prurigo nodularis, Clinical trial, Patient, III, The New England Journal of Medicine, Multimedia, Pharmaceutical industry, Galderma, Medicine

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.

Key Points:

Galderma today announced that the New England Journal of Medicine has published full results from the phase III OLYMPIA 2 trial evaluating the efficacy and safety of nemolizumab monotherapy in adults with prurigo nodularis.
Nemolizumab was well tolerated, and its safety profile was consistent with phase II trial results.1
This press release features multimedia.
Results from the phase III OLYMPIA 2 trial will be submitted to selected health authorities around the world.
To learn more about prurigo nodularis, watch this video from the New England Journal of Medicine.

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Retrieved on:

Thursday, October 26, 2023

Female, Pattern hair loss, Technology transfer, AGA, III, CMC, CDMO, EM, Hair, Biopharmaceutical, Patient, Mab, Endometriosis, BLA, Vaccine, Pharmaceutical industry

Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.

Key Points:

Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.
Hope Medicine will leverage Chime Biologics' extensive experience in 2000L cGMP manufacturing, late-stage CMC development and BLA filings to jointly accelerate HMI-115 mAb development and manufacturing for speedy clinical advancement of targeting endometriosis and androgenetic alopecia, benefiting more female patients and alopecia patients.
Dr. Damian Tu, President of Hope Medicine, said, "HMI-115 is Hope Medicine's most critical and advanced clinical antibody drug asset.
Dr. Jimmy Wei, President of Chime Biologics, said, "We are pleased to be a strategic partner of Hope Medicine.

Bank of Botetourt posts profitable third quarter financial results

Retrieved on:

Thursday, October 26, 2023

Insurance, Sale, Bank, III, Family, Interest, Economic growth, Dividend, Consumer Protection Act, Real estate, Cryptocurrency, Holding company, Life insurance, Botetourt

BUCHANAN, Va., Oct. 26, 2023 /PRNewswire/ -- Buchanan-based Bank of Botetourt (OTCPK: BORT and BORTP) announced today its unaudited financial results for the three and nine months-end September 30, 2023.

Key Points:

BUCHANAN, Va., Oct. 26, 2023 /PRNewswire/ -- Buchanan-based Bank of Botetourt (OTCPK: BORT and BORTP) announced today its unaudited financial results for the three and nine months-end September 30, 2023.
CEO & Vice-Chairman, G. Lyn Hayth, III stated "Despite navigating a challenging net interest margin landscape, we produced strong financial results for the third quarter.
Bank of Botetourt qualified to opt-in to the Community Bank Leverage Ratio ("CBLR").
As of September 30, 2023 Bank of Botetourt reported its CBLR ratio at 10.51% which meets the required regulatory minimum ratio.

Pinnacle Bankshares Corporation Announces Record High 3rd Quarter & Year-to-Date 2023 Earnings

Retrieved on:

Tuesday, October 24, 2023

ALTAVISTA, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Net income for Pinnacle Bankshares Corporation (OTCQX:PPBN), the one-bank holding company (the “Company” or “Pinnacle”) for First National Bank (the “Bank”), was a record high $2,794,000, or $1.27 per basic and diluted share, for the third quarter of 2023.

Key Points:

ALTAVISTA, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Net income for Pinnacle Bankshares Corporation (OTCQX:PPBN), the one-bank holding company (the “Company” or “Pinnacle”) for First National Bank (the “Bank”), was a record high $2,794,000, or $1.27 per basic and diluted share, for the third quarter of 2023.
Net income for the nine months ended September 30, 2023, was $7,483,000, or $3.41 per basic and diluted share, also a record high.
Third Quarter & Year-to-Date Highlights include the following:
Record High Third Quarter 2023 Net Income of $2,794,000 surpassed the previous quarterly record high net income of $2,639,000, achieved in the first quarter of 2023.
The Loan Portfolio grew $6.1 million dollars over the last two months of the third quarter of 2023.

SCWorx Signs Letter of Intent to Acquire an Environmental Services Company

Retrieved on:

Monday, October 23, 2023

AEPT, Stanton Park, WORX, American Energy Partners, LP, OTC, News, Acquisition, Biophysical environment, Transaction, North American Environmental Atlas, Data management, Bank statement, LOI, III, Letter, Cryptocurrency, Commercial property, COVID-19

New York, NY, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SCWorx Corp (the "Company" or “SCWorx”)) (Nasdaq: WORX) is pleased to announce that on October 20, 2023 it entered into a letter of intent to acquire American Environmental Partners, Inc (Formerly American Energy Partners, Inc) ("American Environmental") (OTC: AEPT) (the "LOI").

Key Points:

New York, NY, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SCWorx Corp (the "Company" or “SCWorx”)) (Nasdaq: WORX) is pleased to announce that on October 20, 2023 it entered into a letter of intent to acquire American Environmental Partners, Inc (Formerly American Energy Partners, Inc) ("American Environmental") (OTC: AEPT) (the "LOI").
The Company anticipates that Proposed Transaction will be structured as a share-for-share exchange with SCWorx shareholders retaining 17% of the combined Company, after giving effect to a $6 million capital raise by American Environmental, which is a condition to completion of the Proposed Transaction.
The binding components require among other things that American Environmental Partners provide the Company $150,000 of working capital, as well as cover its costs to complete the transaction.
The acquisition of American Environmental will substantially increase the consolidated revenue of the Company, better enabling it to absorb public company costs, while improving cashflow which should enable both SCWorx and American Environmental to grow their respective client bases and revenue.”

Jonathan Milner Issues Statement Responding to the Glass Lewis Report

Retrieved on:

Monday, October 23, 2023

ACT, MAKE, ITS, TAX, FOR, PAST, FAIR, DATE, AS, UPDATE, SET, ANY, NO, AMERICA, FCA, EUROPEAN UNION, BY, FUTURE, FINANCIAL, III, TIME, UPON, NOT, EACH, AND, ALL, PER, THIS, OF, EXPRESS, AWARE, IS, NORTH, USE, IT, Glass fiber, Medical device, Audit, EU

T: +44 7733 265 198 / E: [email protected]

Key Points:

T: +44 7733 265 198 / E: [email protected]
T: +44 (0)20 3709 5700 / E: [email protected]
T: +1 646 677 1811 / E: [email protected]
THIS DOCUMENT HAS BEEN ISSUED BY DR. JONATHAN MILNER ("DR. MILNER").
DR. MILNER STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF DR. MILNER AS OF THE DATE HEREOF.
DR. MILNER HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION CONTAINED HEREIN.

Vistant Named Again as One of the Fastest-Growing Companies in Greater Washington D.C. Area by Washington Business Journal

Retrieved on:

Friday, October 20, 2023

State government, III, WBJ, Real estate

“We’re fortunate to have a team that’s fully committed to supporting our clients’ missions,” said Walter Barnes, III, Vistant’s president.

Key Points:

“We’re fortunate to have a team that’s fully committed to supporting our clients’ missions,” said Walter Barnes, III, Vistant’s president.
The list identifies the top 50 companies across the greater DC area that navigated continuing economic uncertainties post-pandemic and still saw extraordinary revenue growth between 2022 and 2023.
To qualify, companies must be locally headquartered and privately owned, having no parent company.
Earlier this year, Vistant was also named to the Inc. 5000 list for the fifth consecutive year.

Dxcover Awarded First Prize for Poster at ESMO 2023 With Multi-Omic Spectral Analysis in Early Detection of Multiple Cancers Data

Retrieved on:

Wednesday, October 25, 2023

Dxcover Limited , a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that it has been awarded first prize for its poster focused on the detection of early-stage tumors across multiple cancers at the European Society for Medical Oncology (ESMO) Congress 2023 in the Innovative Diagnostic Tools category.

Key Points:

Dxcover Limited , a clinical-stage liquid biopsy company pioneering Multi-Omic Spectral Analysis for early detection of cancer, today announced that it has been awarded first prize for its poster focused on the detection of early-stage tumors across multiple cancers at the European Society for Medical Oncology (ESMO) Congress 2023 in the Innovative Diagnostic Tools category.
The poster titled “A Spectroscopic Liquid Biopsy for the Earlier Detection of Multiple Cancers” is based on a study which was recently published in the British Journal of Cancer.
The cancer versus asymptomatic non-cancer classification detected 64% of stage I cancers when specificity was 99%, with an overall sensitivity of 56%.
“It is an honor to be recognized by such an esteemed organization as ESMO for Dxcover’s Multi-Omic Spectral Analysis.

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease

Retrieved on:

Wednesday, October 25, 2023

The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.

Key Points:

The vaccine elicited an immune response in adults aged 50 to 59 at increased risk for RSV disease due to select underlying medical conditions that was non-inferior to that observed in adults aged 60 and above, meeting the trial’s primary co-endpoint.
The co-primary endpoint was also met for the broader group of adults aged 50 to 59 also enrolled in the trial.
Tony Wood, Chief Scientific Officer, GSK, said: “This trial reinforces our confidence in our RSV vaccine’s ability to help protect adults aged 50 to 59 at increased risk for RSV-LRTD.
Immune response in participants aged 50 to 59 with pre-defined stable chronic diseases leading to an increased risk of RSV disease was assessed (n=570).